ALEMBIC
GenericsALEMBIC is a generic drug manufacturer focused on Cardiovascular, Neurology, Oncology.
ALEMBIC's Key Drugs
ALEMBIC's core commercial portfolio centers on DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), LOTEPREDNOL ETABONATE AND TOBRAMYCIN, AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.
Breast Cancer
Inflammatory Ocular Conditions
Hypertension
Gastrointestinal Disorder
Hypertension
ALEMBIC's Recent FDA Approvals
ALEMBIC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
ALEMBIC's Therapeutic Areas
ALEMBIC's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ALEMBIC's Top Competitors
ALEMBIC's closest competitors by therapeutic-area and drug-target overlap include Merck, GE HEALTHCARE, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ALEMBIC Pipeline Snapshot
ALEMBIC has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (12)
Discontinued (4)
Company Info
- First Approval
- 2009-01-12
- Latest
- 2026-11-03
- Applications
- 214